Christopher Lindop - PAREXEL International Independent Director
Director
Mr. Christopher J. Lindop is Independent Director of Parexel International Corporationrationration. He is Chairman of the Audit and Finance Committee and a member of the Nominating and Corporationrationrate Governance Committee. From January 2007 to June 2016, Mr. Lindop served as Chief Financial Officer and Executive Vice President, Business Development of Haemonetics Corporationrationration, a global blood management company. From September 2003 to December 2006, he served as Chief Financial Officer of Inverness Medical Innovations, Inc., a global developer, manufacturer and marketer of medical diagnostic products. From June 2002 to September 2003, he served as an audit partner for Ernst Young LLP, an accounting firm. From 1991 to June 2002, Mr. Lindop served as an audit partner with the Boston office of Arthur Andersen LLP, an accounting firm. since 2006.
| Age | 57 |
| Tenure | 18 years |
| Phone | 781 487-9900 |
| Web | http://www.parexel.com |
PAREXEL International Management Efficiency
The company has return on total asset (ROA) of 0.0471 % which means that it generated a profit of $0.0471 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.15 %, meaning that it created $0.15 on every $100 dollars invested by stockholders. PAREXEL International's management efficiency ratios could be used to measure how well PAREXEL International manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 671.5 M in liabilities with Debt to Equity (D/E) ratio of 105.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PAREXEL International has a current ratio of 1.42, which is within standard range for the sector. Debt can assist PAREXEL International until it has trouble settling it off, either with new capital or with free cash flow. So, PAREXEL International's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PAREXEL International sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PAREXEL to invest in growth at high rates of return. When we think about PAREXEL International's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Tom Heinen | Where Food Comes | 58 | |
| Naren Gursahaney | Nextera Energy | 59 | |
| David Bronczek | Tyson Foods | 66 | |
| Robert Thurber | Tyson Foods | 72 | |
| Pete Lapaseotes | Where Food Comes | 55 | |
| Brad Sauer | Tyson Foods | 55 | |
| Robert Beall | Nextera Energy | 70 | |
| Les Baledge | Tyson Foods | 61 | |
| Adam Larson | Where Food Comes | 44 | |
| Barbara Tyson | Tyson Foods | 71 | |
| Hansel Tookes | Nextera Energy | 71 | |
| Sherry Barrat | Nextera Energy | 71 | |
| Kenneth Dunn | Nextera Energy | 69 | |
| Jeffrey Schomburger | Tyson Foods | 58 | |
| Jonathan Mariner | Tyson Foods | 66 | |
| Mikel Durham | Tyson Foods | 57 | |
| Kristin Rose | Nextera Energy | N/A | |
| Toni Jennings | Nextera Energy | 71 | |
| Darryl Wilson | Nextera Energy | 57 | |
| Kirk Hachigian | Nextera Energy | 61 | |
| Robert VanSchoick | Where Food Comes | 63 | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0471 |
PAREXEL International Leadership Team
Elected by the shareholders, the PAREXEL International's board of directors comprises two types of representatives: PAREXEL International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PAREXEL. The board's role is to monitor PAREXEL International's management team and ensure that shareholders' interests are well served. PAREXEL International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PAREXEL International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michelle Graham, Chief Human Resource Officer, Senior Vice President | ||
| Ulf Schneider, Chief Administrative Officer, Senior Vice President | ||
| Thomas Senderovitz, Senior Vice President - Clinical Research Services | ||
| Dana Callow, Presiding Independent Director | ||
| Emma Reeve, Interim CFO, Corporate Vice President Controller | ||
| Josef Rickenbach, Founder, Chairman and CEO | ||
| Patrick Fortune, Independent Director | ||
| Eduard Holdener, Independent Director | ||
| Simon Harford, CFO, Senior Vice President | ||
| Joshua Schultz, Senior Vice President-Worldwide Head of PAREXEL Access | ||
| Gadi Saarony, Senior Vice President - Clinical Research Services | ||
| Ellen Zane, Director, Member of Compensation Committee, Member of HR Committee, CEO of Tufts Medical Center and President of Tufts Medical Center | ||
| Christian Dreger, Senior Vice President - Parexel Access and Parexel Consulting | ||
| Xavier Flinois, President - Perceptive Informatics | ||
| Douglas Batt, Sr. VP, General Counsel and Secretary | ||
| Sybrand Pretorius, Senior Vice President Chief Scientific Officer | ||
| Maykin Ho, Director | ||
| Richard Love, Independent Director | ||
| Ronald Aldridge, Sr. Director, Investor Relations | ||
| Mark Goldberg, President COO | ||
| Roland Andersson, Senior Vice President - Clinical Research Services | ||
| Christopher Lindop, Independent Director | ||
| Ingo Bank, CFO and Sr. VP | ||
| David Godwin, Senior Vice President-Global Business |
PAREXEL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PAREXEL International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0471 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 11.04 % | |||
| Current Valuation | 4.87 B | |||
| Shares Outstanding | 51.12 M | |||
| Shares Owned By Insiders | 2.00 % | |||
| Shares Owned By Institutions | 90.14 % | |||
| Number Of Shares Shorted | 506.64 K | |||
| Price To Earning | 42.76 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PAREXEL International in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PAREXEL International's short interest history, or implied volatility extrapolated from PAREXEL International options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PAREXEL International using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in PAREXEL Stock
If you are still planning to invest in PAREXEL International check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PAREXEL International's history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |